• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

22.07 +0.49 (+2.27%)
Streaming Delayed Price Updated: 4:00 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,390,257
Open 21.00
Bid (Size) 22.00 (500)
Ask (Size) 22.39 (100)
Prev. Close 21.58
Today's Range 21.00 - 22.20
52wk Range 8.580 - 22.73
Shares Outstanding 69,484,053
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
March 04, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax (SNDX) Q4 2025 Earnings Call Transcript ↗
February 27, 2026
Syndax (SNDX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings

Performance

YTD
+3.6%
+3.6%
1 Month
+9.5%
+9.5%
3 Month
+10.5%
+10.5%
6 Month
+35.2%
+35.2%
1 Year
+64.5%
+64.5%

More News

Read More
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Reports Mixed Q4 2025 Results with Revenue Beat and Wider-Than-Expected Loss ↗
February 26, 2026
Via Chartmill
News headline image
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 3, 2025 ↗
November 03, 2025
Via Benzinga
News headline image
Syndax Pharmaceuticals's Earnings Outlook ↗
October 31, 2025
Via Benzinga
News headline image
Syndax Announces Participation in March Investor Conferences
February 23, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026
February 19, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
February 05, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 04, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
January 07, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
December 22, 2025
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
December 12, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
December 08, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 03, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
December 01, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 05, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
November 03, 2025
Via Benzinga
News headline image
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
November 03, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
November 03, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
November 03, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Announces Participation in November Investor Conferences
October 30, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
October 27, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Syndax Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Syndax Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Syndax Pharmaceuticals, Inc. - Common Stock trade on?
Syndax Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock is SNDX on the Nasdaq Stock Market
What is the current price of Syndax Pharmaceuticals, Inc. - Common Stock?
The current price of Syndax Pharmaceuticals, Inc. - Common Stock is 22.07
When was Syndax Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Syndax Pharmaceuticals, Inc. - Common Stock was at 03/06/26 04:00 PM ET
What is the market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock is 1.53B
How many shares of Syndax Pharmaceuticals, Inc. - Common Stock are outstanding?
Syndax Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap